Skip to main content
SpringerLink
Log in

Granulocyte Colony-Stimulating Factor: Biology and Clinical Potential

  • Chapter
Principles of Cancer Biotherapy

  • 106 Accesses

Abstract

The study of hematopoiesis was greatly facilitated in the mid-1960s when techniques for studying hematopoietic cells in clonal culture were developed. Initially, serum or conditioned medium was added to cultures as a source of growth factors, the colony-stimulating factors (CSFs) [41]. Subsequently, four different CSFs that controlled the growth of granulocytes and macrophages were identified. In the early 1980s, the gene for granulocyte-macrophage colony-stimulating factor (GM-CSF) was cloned, and by the close of the decade, all four genes for the identified CSFs had been cloned for human and murine forms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asano S, Sato N, Mori M, et al. Detection and assessment of human granulocyte-macrophage colony-stimulating factor (GM-CSF) producing tumours by heterotransplantation into nude mice. Br J Cancer 1980; 41: 689–694.

    Article  PubMed  CAS  Google Scholar 

  2. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Ped Hematol/Oncol 1991; 13:400–413.

    Article  CAS  Google Scholar 

  3. Azuma J, Kurimoto T, Awata S, et al. Phase I study of KRN 8601 (rhG-CSF) in normal healthy volunteers: safety and pharmacokinetics in single subcutaneous administration. Rinsholyaku 1989; 5: 2231–2252.

    Google Scholar 

  4. Bessho M, Toyoda A, Itoh Y, et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor (rhGCSF) and erythropoietin (rhEPO) in severe aplastic anemia. Br J Haematol 1992; 80:409–411.

    Article  PubMed  CAS  Google Scholar 

  5. Bronchud MH, Howell A, Crother D, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121–128.

    Article  PubMed  CAS  Google Scholar 

  6. Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58: 64–69.

    Article  PubMed  CAS  Google Scholar 

  7. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.Br J Cancer 1987; 56: 809–813.

    Article  PubMed  CAS  Google Scholar 

  8. Cebon JS, Layton JE, Maher D, Morstyn G. ndogenous haemopoietic* growth factors in neutropenia and infection. Br J Haematol 1994; 86: 263–274.

    Article  Google Scholar 

  9. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colonystimulating factor ’mobilized’ peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035.

    PubMed  CAS  Google Scholar 

  10. Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of Filgrastim (r-metHuG-CSF) on oral mucositis patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proc ASCO 1994; 13:442 (abstract 1523).

    Google Scholar 

  11. Crawford J, Kreisman H, Garewal H, et al. A pharmacodynamic investigation of recombinant human granulocyte colony stimulating factor (r-metHuG-SCF) schedule variation in patients with small cell lung cancer (SCLC) given CAE chemotherapy. J Clin Oncol 1992; 11: 299 (abstract 1005).

    Google Scholar 

  12. Crawford J. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Eng J Med 1991; 325: 164–170.

    Article  CAS  Google Scholar 

  13. Dale DC, Bonilla MA, Davis MS, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496–2502.

    PubMed  CAS  Google Scholar 

  14. Dale DC, Hammond WP, Gabrilove J, et al. Long term treatment of severe chronic neutropenia with recombinant human granulocyte colony-stimulating factor (r-metHuGCSF). Blood 1990; 76: 139A (abstract 545).

    Google Scholar 

  15. Demetri G, Younger J, McGuire BW, et al. Recombinant methionyl granulocyte-CSF (r-metG-CSF) allows an increase in the dose intensity of cyclophosphamide / doxorubicin / 5-fluorouracil (CAF) in patients with advanced breast cancer. Proc ASCO 1991; 10: 70 (abstract 153).

    Google Scholar 

  16. Decoster G, Rich W, Brown SL. Safety profile of Filgrastim (r-metHuG-CSF). IN: Filgrastim (r-metHuGCSF) in Clinical Practice. G Morstyn and TM Dexter, ed. Marcel Dekker, Inc. New York, NY. 1994; pages 267–290.

    Google Scholar 

  17. Dürhsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074–2081.

    Google Scholar 

  18. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82: 1454–1461.

    Article  PubMed  CAS  Google Scholar 

  19. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitionalcell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414–1422.

    Article  PubMed  CAS  Google Scholar 

  20. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 1993; 82: 196a (abstract768).

    Google Scholar 

  21. Harousseau JL. Lenograstim after bone marrow transplantation: results of a European multicenter randomised study in 315 patients. Satellite Symposium to the 24th Congress of the ISH; 1992.

    Google Scholar 

  22. Hohaus S, Goldschmidt H, Ehrhardt R, Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.Exp Hematol 1993; 21: 508–514.

    PubMed  CAS  Google Scholar 

  23. Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drug Evaluation 1991; 42: 300–330.

    CAS  Google Scholar 

  24. Jacobsen MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colonystimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992; 6: 515–517.

    Article  Google Scholar 

  25. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990; 76: 1962–1964.

    PubMed  CAS  Google Scholar 

  26. Kawano Y, Takaue Y, Watanabe T, et al. Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. Exp Hematol 1993; 21: 103–108.

    PubMed  CAS  Google Scholar 

  27. Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K. Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood 1991; 77:937–941.

    PubMed  CAS  Google Scholar 

  28. Kuga T, Komatsu Y, Yamaski M, et al. Mutagenesis of human granulocyte colony stimulating factor. Biochem Biophys Res Comm 1989; 159: 103–111.

    Article  PubMed  CAS  Google Scholar 

  29. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994; 84: 1737–1746.

    PubMed  CAS  Google Scholar 

  30. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28–35.

    Article  PubMed  CAS  Google Scholar 

  31. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992; 327: 99–016.

    Article  PubMed  CAS  Google Scholar 

  32. Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colonystimulating factor. Blood 1989; 74A: 2634–2643.

    Google Scholar 

  33. Lieschke GJ, Morstyn G. Role of G-CSF and GM-CSF in the prevention of chemotherapy-induced neutropenia; IN: Hematopoietic Growth Factors in Clinical Applications; R Mertelsmann and F Herrmann, eds; 1990; pages 191-223.

    Google Scholar 

  34. Linch DC, Scarrffe H, Proctor S, et al. Randomised vehicle-controlled dose finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11:307–311.

    PubMed  CAS  Google Scholar 

  35. Linch DC. Lenograstim, a new glycosylated rHuG-CSF: Pharmacology and clinical profile in bone marrow transplants. Br J Haematol 1992; 82: 274–275.

    Google Scholar 

  36. Lindemann A, Herrmann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colonystimulating factor in patients with malignancy. Blood 1989; 74:2644–2651.

    PubMed  CAS  Google Scholar 

  37. Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 1989; 86:9499–9503.

    Article  PubMed  CAS  Google Scholar 

  38. Lord BI, Gurney H, Chang J, et al. Haemopoietic cell kinetics in humans treated with rGM-CSF. Int J Cancer 1992; 50:26–31.

    Article  PubMed  CAS  Google Scholar 

  39. Maher DW, Lieschke GJ, Green M, et al. Filgrastim (rmetHuG- CSF) in patients with chemotherapy-induced febrile neutropenia. Ann Int Med 1994; 121: 492–501.

    PubMed  CAS  Google Scholar 

  40. Metcalf D. Clonal extinction of myelomonocytic leukaemia cells by serum from mice injected with endotoxin. Int J Cancer 1980; 25: 225–233.

    Article  PubMed  CAS  Google Scholar 

  41. Metcalf D. The Molecular Control of Blood Cells. Harvard University Press. Cambridge, MS; 1988.

    Google Scholar 

  42. Metcalf D, Morstyn G. Colony Stimulating Factors: General Biology. IN: Biologic Therapy of Cancer, V DeVita, ed; Philadelphia, JB Lippincott; 1991; pages 417–444.

    Google Scholar 

  43. Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77: 2109–2117.

    PubMed  CAS  Google Scholar 

  44. Morstyn G, Burgess AW. Hemopoietic growth factors: a review. Cancer Res 1988; 48: 5624–5637.

    PubMed  CAS  Google Scholar 

  45. Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989;7:1554–1562.

    PubMed  CAS  Google Scholar 

  46. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667–672.

    Article  PubMed  CAS  Google Scholar 

  47. Morstyn G, Lieschke GJ, Cebon J, et al. Early clinical trials with colony-stimulating factors. Cancer Invest 1989b; 7: 443–456.

    Article  PubMed  CAS  Google Scholar 

  48. Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 7: 36–43.

    Google Scholar 

  49. Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing differentiation in murine myelomonocytic leukaemia cells: identification as granulocyte colony-stimulating factor (G-CSF). J Biol Chem 1983;258:9017–9023.

    PubMed  CAS  Google Scholar 

  50. Nicola NA. Hemopoietic cell growth factors and their receptors. Annu Rev Biochem 1989; 58: 45–77.

    Article  PubMed  CAS  Google Scholar 

  51. Nio Y, Shiraishi T, Tsubono M, et al. Comparative effects of a recombinant and a mutein type of granulocyte colony stimulating factor on the growth of Meth-A fibrosarcoma with 5-fluorouracil chemotherapy. Biotherapy 1992; 4: 81– 86.

    Google Scholar 

  52. Nomura H, Imazeki I, Oheda M, et al. Purification and characterization of human granulocyte colony stimulating factor (G-CSF). EMBO J 1986; 5: 871–876.

    PubMed  CAS  Google Scholar 

  53. Osslund T, Boone TC. Biochemistry and structure of Filgrastim (r-metHuG-CSF). IN: Filgrastim (r- metHuGCSF) in Clinical Practice. G Morstyn and TM Dexter, ed. Marcel Dekker, Inc. New York, NY. 1994; pages 23–31.

    Google Scholar 

  54. Peters WP, Kurtzberg J, Atwater S, et al. Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function following high dose chemotherapy and autologous bone marrow transplantation (ABMT). Proc ASCO 1989; 18: 18A.

    Google Scholar 

  55. Pettengell R, Gurney H, Radford J, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436.

    PubMed  CAS  Google Scholar 

  56. Platzer E. Human hemopoietic growth factors. Eur J Haematol 1989; 42:1–15.

    Article  PubMed  CAS  Google Scholar 

  57. Rapoport AP, Abboud CN, DiPersio JF. Granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Reviews 1992; 6:43–57.

    Article  PubMed  CAS  Google Scholar 

  58. Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–1951.

    PubMed  CAS  Google Scholar 

  59. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11: 2010–2020.

    PubMed  CAS  Google Scholar 

  60. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of MVAC with recombinant granulocyte colonystimulating factor in the treatment of advanced urothelial cancer. J Clin Oncol 1993; 11: 408–414.

    PubMed  CAS  Google Scholar 

  61. Sekino H, Moriya K, Sugano T, Wakabayashi K, Okazaki A. Recombinant human G-CSF (rG-CSF). Shinryo to Shinyaku 1989; 26:32–104.

    Google Scholar 

  62. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644.

    Article  PubMed  CAS  Google Scholar 

  63. Sheridan WP, Juttner C, Szer J, et al. Granulocyte colonystimulating factor (G-CSF) in peripheral blood stem cell (PBSC) and bone marrow transplantation. Blood 1990; 76: SI.

    Google Scholar 

  64. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895.

    Article  PubMed  CAS  Google Scholar 

  65. Steward WP. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993; 342; 153–157.

    Article  PubMed  CAS  Google Scholar 

  66. Taylor KM, Jagganath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin’s disease. J Clin Oncol 1989; 7: 1791–1799.

    PubMed  CAS  Google Scholar 

  67. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–324.

    Article  PubMed  CAS  Google Scholar 

  68. Van derWouw PA, vanLeeuwen R, vanOers RH, et al. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase 1/11 study. Br J Haematol 1991; 78: 319–324.

    Article  Google Scholar 

  69. Vellenga E, Rambaldi A, Ernst TJ, Ostapovicz D, Griffin JD. Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood 1988; 71: 1529–1532.

    PubMed  CAS  Google Scholar 

  70. Watari K, Asano S, Shirafuji N, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989; 73: 117–122.

    PubMed  CAS  Google Scholar 

  71. Weisbart RH, Golde DW. Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin of North Am 1989; 3:401–409.

    CAS  Google Scholar 

  72. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82: 1526–1530.

    Article  PubMed  CAS  Google Scholar 

  73. Welte K, Ziedler C, Reiter A, et al. Differential effects of granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056–1063.

    PubMed  CAS  Google Scholar 

  74. Wong GG, Witek JS, Temple PA, et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985;228:810–815.

    Article  PubMed  CAS  Google Scholar 

  75. Young JD, Cheung EN, Tanaka H, Hasibeder H, Asano K, Shimosaka A. Bioavailability of subcutaneously administered non-glycosylated recombinant hG-CSF (Filgrastim) in normal and neutropenic rats. Proc ASCO 1994; 13: 162 (abstract 443).

    Google Scholar 

  76. Yoshida Y, Hirashima K, Asano S, et al. A phase 11 trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991; 78: 378–384.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Amgen Inc., Thousand Oaks, California, USA

    George Morstyn, Maryann Foote, Dianne Tomita & Rosemary Mazanet

  2. UCLA Medical School, Los Angeles, California, USA

    George Morstyn

  3. Duke University Medical School, Durham, North Carolina, USA

    Jeffrey Crawford

  4. Centre Hospitalier, Lyon Sud, France

    Veronique Trillet-Lenoir

  5. CSL Limited, Victoria, Australia

    Darryl Maher

  6. Amgen Inc, Cambridge, UK

    James Matcham

Authors
  1. George Morstyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maryann Foote
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Veronique Trillet-Lenoir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Darryl Maher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dianne Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James Matcham
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rosemary Mazanet
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham M.D. (Clinical Professor of Medicine) (Clinical Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Morstyn, G. et al. (1998). Granulocyte Colony-Stimulating Factor: Biology and Clinical Potential. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0029-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0029-5_19

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6501-6

  • Online ISBN: 978-94-009-0029-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation